Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure

Rishi J. Desai, Carol M. Ashton, Anita Deswal, Robert O. Morgan, Hemalkumar Mehta, Hua Chen, Rajender R. Aparasu, Michael L. Johnson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: There is little evidence on comparative effectiveness of individual angiotensin receptor blockers (ARBs) in patients with chronic heart failure (CHF). This study compared four ARBs in reducing risk of mortality in clinical practice. Methods: A retrospective analysis was conducted on a national sample of patients diagnosed with CHF from 1 October 1996 to 30 September 2002 identified from Veterans Affairs electronic medical records, with supplemental clinical data obtained from chart review. After excluding patients with exposure to ARBs within the previous 6months, four treatment groups were defined based on initial use of candesartan, valsartan, losartan, and irbesartan between the index date (1 October 2000) and the study end date (30 September 2002). Time to death was measured concurrently during that period. A marginal structural model controlled for sociodemographic factors, comorbidities, comedications, disease severity (left ventricular ejection fraction), and potential time-varying confounding affected by previous treatment (hospitalization). Propensity scores derived from a multinomial logistic regression were used as inverse probability of treatment weights in a generalized estimating equation to estimate causal effects. Results: Among the 1536 patients identified on ARB therapy, irbesartan was most frequently used (55.21%), followed by losartan (21.74%), candesartan (15.23%), and valsartan (7.81%). When compared with losartan, after adjusting for time-varying hospitalization in marginal structural model, candesartan (OR=0.79, 95%CI=0.42-1.50), irbesartan (OR=1.17, 95%CI=0.72-1.90), and valsartan (OR=0.98, 95%CI=0.45-2.14) were found to have similar effectiveness in reducing mortality in CHF patients. Conclusion: Effectiveness of ARBs in reducing mortality is similar in patients with CHF in everyday clinical practice.

Original languageEnglish (US)
Pages (from-to)233-240
Number of pages8
JournalPharmacoepidemiology and Drug Safety
Volume21
Issue number3
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

irbesartan
Angiotensin Receptor Antagonists
Valsartan
Heart Failure
Losartan
Mortality
Structural Models
Hospitalization
Propensity Score
Electronic Health Records
Veterans
Therapeutics
Stroke Volume
Comorbidity
Logistic Models
Weights and Measures
candesartan

Keywords

  • Angiotensin receptor blockers
  • Comparative effectiveness
  • Marginal structural models

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology

Cite this

Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. / Desai, Rishi J.; Ashton, Carol M.; Deswal, Anita; Morgan, Robert O.; Mehta, Hemalkumar; Chen, Hua; Aparasu, Rajender R.; Johnson, Michael L.

In: Pharmacoepidemiology and Drug Safety, Vol. 21, No. 3, 03.2012, p. 233-240.

Research output: Contribution to journalArticle

Desai, RJ, Ashton, CM, Deswal, A, Morgan, RO, Mehta, H, Chen, H, Aparasu, RR & Johnson, ML 2012, 'Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure', Pharmacoepidemiology and Drug Safety, vol. 21, no. 3, pp. 233-240. https://doi.org/10.1002/pds.2175
Desai, Rishi J. ; Ashton, Carol M. ; Deswal, Anita ; Morgan, Robert O. ; Mehta, Hemalkumar ; Chen, Hua ; Aparasu, Rajender R. ; Johnson, Michael L. / Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. In: Pharmacoepidemiology and Drug Safety. 2012 ; Vol. 21, No. 3. pp. 233-240.
@article{6fa0e60b8cbc4c908a8833b4b1996481,
title = "Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure",
abstract = "Objective: There is little evidence on comparative effectiveness of individual angiotensin receptor blockers (ARBs) in patients with chronic heart failure (CHF). This study compared four ARBs in reducing risk of mortality in clinical practice. Methods: A retrospective analysis was conducted on a national sample of patients diagnosed with CHF from 1 October 1996 to 30 September 2002 identified from Veterans Affairs electronic medical records, with supplemental clinical data obtained from chart review. After excluding patients with exposure to ARBs within the previous 6months, four treatment groups were defined based on initial use of candesartan, valsartan, losartan, and irbesartan between the index date (1 October 2000) and the study end date (30 September 2002). Time to death was measured concurrently during that period. A marginal structural model controlled for sociodemographic factors, comorbidities, comedications, disease severity (left ventricular ejection fraction), and potential time-varying confounding affected by previous treatment (hospitalization). Propensity scores derived from a multinomial logistic regression were used as inverse probability of treatment weights in a generalized estimating equation to estimate causal effects. Results: Among the 1536 patients identified on ARB therapy, irbesartan was most frequently used (55.21{\%}), followed by losartan (21.74{\%}), candesartan (15.23{\%}), and valsartan (7.81{\%}). When compared with losartan, after adjusting for time-varying hospitalization in marginal structural model, candesartan (OR=0.79, 95{\%}CI=0.42-1.50), irbesartan (OR=1.17, 95{\%}CI=0.72-1.90), and valsartan (OR=0.98, 95{\%}CI=0.45-2.14) were found to have similar effectiveness in reducing mortality in CHF patients. Conclusion: Effectiveness of ARBs in reducing mortality is similar in patients with CHF in everyday clinical practice.",
keywords = "Angiotensin receptor blockers, Comparative effectiveness, Marginal structural models",
author = "Desai, {Rishi J.} and Ashton, {Carol M.} and Anita Deswal and Morgan, {Robert O.} and Hemalkumar Mehta and Hua Chen and Aparasu, {Rajender R.} and Johnson, {Michael L.}",
year = "2012",
month = "3",
doi = "10.1002/pds.2175",
language = "English (US)",
volume = "21",
pages = "233--240",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure

AU - Desai, Rishi J.

AU - Ashton, Carol M.

AU - Deswal, Anita

AU - Morgan, Robert O.

AU - Mehta, Hemalkumar

AU - Chen, Hua

AU - Aparasu, Rajender R.

AU - Johnson, Michael L.

PY - 2012/3

Y1 - 2012/3

N2 - Objective: There is little evidence on comparative effectiveness of individual angiotensin receptor blockers (ARBs) in patients with chronic heart failure (CHF). This study compared four ARBs in reducing risk of mortality in clinical practice. Methods: A retrospective analysis was conducted on a national sample of patients diagnosed with CHF from 1 October 1996 to 30 September 2002 identified from Veterans Affairs electronic medical records, with supplemental clinical data obtained from chart review. After excluding patients with exposure to ARBs within the previous 6months, four treatment groups were defined based on initial use of candesartan, valsartan, losartan, and irbesartan between the index date (1 October 2000) and the study end date (30 September 2002). Time to death was measured concurrently during that period. A marginal structural model controlled for sociodemographic factors, comorbidities, comedications, disease severity (left ventricular ejection fraction), and potential time-varying confounding affected by previous treatment (hospitalization). Propensity scores derived from a multinomial logistic regression were used as inverse probability of treatment weights in a generalized estimating equation to estimate causal effects. Results: Among the 1536 patients identified on ARB therapy, irbesartan was most frequently used (55.21%), followed by losartan (21.74%), candesartan (15.23%), and valsartan (7.81%). When compared with losartan, after adjusting for time-varying hospitalization in marginal structural model, candesartan (OR=0.79, 95%CI=0.42-1.50), irbesartan (OR=1.17, 95%CI=0.72-1.90), and valsartan (OR=0.98, 95%CI=0.45-2.14) were found to have similar effectiveness in reducing mortality in CHF patients. Conclusion: Effectiveness of ARBs in reducing mortality is similar in patients with CHF in everyday clinical practice.

AB - Objective: There is little evidence on comparative effectiveness of individual angiotensin receptor blockers (ARBs) in patients with chronic heart failure (CHF). This study compared four ARBs in reducing risk of mortality in clinical practice. Methods: A retrospective analysis was conducted on a national sample of patients diagnosed with CHF from 1 October 1996 to 30 September 2002 identified from Veterans Affairs electronic medical records, with supplemental clinical data obtained from chart review. After excluding patients with exposure to ARBs within the previous 6months, four treatment groups were defined based on initial use of candesartan, valsartan, losartan, and irbesartan between the index date (1 October 2000) and the study end date (30 September 2002). Time to death was measured concurrently during that period. A marginal structural model controlled for sociodemographic factors, comorbidities, comedications, disease severity (left ventricular ejection fraction), and potential time-varying confounding affected by previous treatment (hospitalization). Propensity scores derived from a multinomial logistic regression were used as inverse probability of treatment weights in a generalized estimating equation to estimate causal effects. Results: Among the 1536 patients identified on ARB therapy, irbesartan was most frequently used (55.21%), followed by losartan (21.74%), candesartan (15.23%), and valsartan (7.81%). When compared with losartan, after adjusting for time-varying hospitalization in marginal structural model, candesartan (OR=0.79, 95%CI=0.42-1.50), irbesartan (OR=1.17, 95%CI=0.72-1.90), and valsartan (OR=0.98, 95%CI=0.45-2.14) were found to have similar effectiveness in reducing mortality in CHF patients. Conclusion: Effectiveness of ARBs in reducing mortality is similar in patients with CHF in everyday clinical practice.

KW - Angiotensin receptor blockers

KW - Comparative effectiveness

KW - Marginal structural models

UR - http://www.scopus.com/inward/record.url?scp=84855199294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855199294&partnerID=8YFLogxK

U2 - 10.1002/pds.2175

DO - 10.1002/pds.2175

M3 - Article

VL - 21

SP - 233

EP - 240

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 3

ER -